M. Chao
Immunology · Cell · 2009–2018
A researcher in the Science corpus: 7 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 36 citations into it
Whom M. Chao trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Chao overall
Papers from M. Chao's perspective
Ordered by how strongly the researchers M. Chao trusts endorse each paper. Same corpus, a different order for every researcher.
- Stem cells, cancer, and cancer stem cells (Nature)
- Integrin-associated protein (CD47) and its ligands. (Trends in Cell Biology)
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (Cell)
- Identification of human brain tumour initiating cells (Nature)
- Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. (New England Journal of Medicine)
- Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells (Nature)
- Cancer stem cells: lessons from leukemia. (Trends in Cell Biology)
- Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. (Cell Stem Cell)
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor (Nature)
- Role of CD47 as a marker of self on red blood cells. (Science)
Their papers
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (2009) — 1,689 citations
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells (2009) — 653 citations
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma (2018) — 890 citations
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors (2012) — 1,535 citations
- Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 (2010) — 737 citations
- Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma (2010) — 1,038 citations
- CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. (2009) — 1,544 citations